Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03222505 · ClinicalTrials.gov registry record · NA

Walk Assist Device to Improve Community Ambulation

A NA study of Stroke, sponsored by Shirley Ryan AbilityLab.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT03222505: Completed NA study of Stroke, sponsored by Shirley Ryan AbilityLab.

NCT03222505 is a NA study of Stroke that has completed, run by Shirley Ryan AbilityLab. The registered enrollment target is 12 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03222505, a NA study of Stroke, has completed, sponsored by Shirley Ryan AbilityLab.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The goal of this research study was to examine the immediate effects of a prototype wearable robotic stride management assist device (SMA) designed by Honda R\&D® on clinical walking performance, walking energetics, gait kinematics and corticospinal excitability in individuals with stroke.

Primary Outcome

The 6 Minute Walk Test (6MWT) is a test of endurance, by measuring the distance a subject can walk indoors on a flat, hard surface in a period of 6 minutes, using assistive devices, as necessary.The distance is measured with a measuring wheel. The instructions are "Walk covering as much ground as you can in 6 min. You can stop to sit or stand if needed."

Conditions Studied

Interventions

  • DEVICE Honda Stride Assist Device ON
  • OTHER No Device Worn

Study Locations (1)

Illinois

  • Rehabilitation Institute of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2010-01
Est. Completion 2018-05
Phase NA
Shirley Ryan AbilityLab

138 total trials

What the finished NCT03222505 record still lists

NCT03222505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Honda Stride Assist Device ON is the first listed.

NCT03222505 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT03222505 about?

NCT03222505 is a clinical study titled "Walk Assist Device to Improve Community Ambulation". The goal of this research study was to examine the immediate effects of a prototype wearable robotic stride management assist device (SMA) designed by Honda R\&D® on clinical walking performance, walking energetics, gait kinematics and corticospinal excitability in individuals with stroke.

What is the current status of trial NCT03222505?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2010-01. Estimated completion is 2018-05.

What conditions does trial NCT03222505 study?

This clinical trial studies the following conditions: Stroke.

What interventions are being tested in trial NCT03222505?

The interventions under investigation include: Honda Stride Assist Device ON (DEVICE), No Device Worn (OTHER).

Who is sponsoring clinical trial NCT03222505?

This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03222505 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03222505's enrollment target sits among peer trials

12 402nd of 454 higher than 47 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03222505, the US trial registry maintained by the National Library of Medicine. NCT03222505 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.